Identification of proteomic signatures of mantle cell lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma biopsies by surface enhanced laser desorption/ionization-time of flight mass spectrometry

References

• Swerdlow SH, Berger F, Isaacson PG, et al. Mantle cell lymphoma. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Lyon: IARC Press; 2001. pp 168–170.
   Google Scholar
• Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification–from controversy to consensus: the REAL and WHO classification of lymphoid neoplasms. Ann Oncol 2000;11(Suppl. 1):3–10.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood 2004;103:2727–2737.
   PubMed Web of Science ®Google Scholar
• Anderson L, Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis 1997;18:533–537.
   PubMed Web of Science ®Google Scholar
• Ginestier C, Charafe-Jauffret E, Bertucci F, et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002;161:1223–1233.
   PubMed Web of Science ®Google Scholar
• Young DS, Tracy RP. Clinical applications of two-dimensional electrophoresis. J Chromatogr A 1995;698:163–179.
   PubMed Web of Science ®Google Scholar
• Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000;21:1164–1177.
   PubMed Web of Science ®Google Scholar
• Reddy G, Dalmasso EA. SELDI ProteinChip(R) array technology: protein-based predictive medicine and drug discovery applications. J Biomed Biotechnol 2003;2003:237–241.
   PubMedGoogle Scholar
• Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292:587–592.
   PubMed Web of Science ®Google Scholar
• Martínez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63:8226–8232.
   PubMed Web of Science ®Google Scholar
• Pang RT, Poon TC, Chan KC, et al. Serum proteomic fingerprints of adult patients with severe acute respiratory syndrome. Clin Chem 2006;52:421–429.
   PubMed Web of Science ®Google Scholar
• Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572–577.
   PubMed Web of Science ®Google Scholar
• Yu Y, Chen S, Wang LS, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 2005;68:79–86.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Ross GF, Dent CL, Devarajan P. Early prediction of acute renal injury using urinary proteomics. Am J Nephrol 2005;25:318–326.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Wu DL, Guan M, et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. Clin Biochem 2004;37:772–779.
   PubMed Web of Science ®Google Scholar
• Carrette O, Demalte I, Scherl A, et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease. Proteomics 2003;3:1486–1494.
   PubMed Web of Science ®Google Scholar
• Sanchez JC, Guillaume E, Lescuyer P, et al. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 2004;4:2229–2233.
   PubMed Web of Science ®Google Scholar
• Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49:1272–1275.
   PubMed Web of Science ®Google Scholar
• Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863–14868.
   PubMed Web of Science ®Google Scholar
• Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–537.
   PubMed Web of Science ®Google Scholar
• Bouamrani A, Ternier J, Ratel D, et al. Direct-tissue SELDI-TOF mass spectrometry analysis: a new application for clinical proteomics. Clin Chem 2006;52:2103–2106.
   PubMed Web of Science ®Google Scholar
• He J, Gornbein J, Shen D, et al. Detection of breast cancer biomarkers in nipple aspirate fluid by SELDI-TOF and their identification by combined liquid chromatography-tandem mass spectrometry. Int J Oncol 2007;30:145–154.
   PubMed Web of Science ®Google Scholar
• Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 2005;11:1073–1085.
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S, et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 2001;158:1491–1502.
   PubMed Web of Science ®Google Scholar
• Koncarevic S, Bogumil R, Becker K. SELDI-TOF-MS analysis of chloroquine resistant and sensitive Plasmodium falciparum strains. Proteomics 2007;7:711–721.
   PubMed Web of Science ®Google Scholar
• Li JY, Gaillard F, Moreau A, et al. Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization. Am J Pathol 1999;154:1449–1452.
   PubMed Web of Science ®Google Scholar
• Rimokh R, Berger F, Bastard C, et al. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 1994;83:3689–3696.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. Cancer cell cycles. Science. 1996;274:1672–1677.
   PubMed Web of Science ®Google Scholar
• Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW, Adams JM. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994;13:2124–2130.
   PubMed Web of Science ®Google Scholar
• Hofmann WK, de Vos S, Tsukasaki K, et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001;98:787–794.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Antonucci F, Chilosi M, Parolini C, Hamdan M, Astner H, Righetti PG. Two-dimensional molecular profiling of mantle cell lymphoma. Electrophoresis 2003;24:2376–2385.
   PubMed Web of Science ®Google Scholar
• Fan G, Molstad M, Braziel RM, et al. Proteomic profiling of mature CD10+ B-cell lymphomas. Am J Clin Pathol 2005;124:920–929.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501–1512.
   PubMed Web of Science ®Google Scholar
• Zhao J, Dynlacht B, Imai T, Hori T, Harlow E. Expression of NPAT, a novel substrate of cyclin E-CDK2, promotes S-phase entry. Genes Dev 1998;12:456–461.
   PubMed Web of Science ®Google Scholar
• Zhao J, Kennedy BK, Lawrence BD, et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000;14:2283–2297.
   PubMed Web of Science ®Google Scholar
• Ye X, Wei Y, Nalepa G, Harper JW. The cyclin E/Cdk2 substrate p220(NPAT) is required for S-phase entry, histone gene expression, and Cajal body maintenance in human somatic cells. Mol Cell Biol 2003;23:8586–8600.
   PubMed Web of Science ®Google Scholar
• Zheng L, Roeder RG, Luo Y. S phase activation of the histone H2B promoter by OCA-S, a coactivator complex that contains GAPDH as a key component. Cell 2003;114:255–266.
   PubMed Web of Science ®Google Scholar
• Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005;131:29–38.
   PubMed Web of Science ®Google Scholar
• Hsu K, Chang DY, Maraia RJ. Human signal recognition particle (SRP) Alu-associated protein also binds Alu interspersed repeat sequence RNAs. Characterization of human SRP9. J Biol Chem 1995;270:10179–10186.
   PubMed Web of Science ®Google Scholar
• Koch HG, Moser M, Müller M. Signal recognition particle-dependent protein targeting, universal to all kingdoms of life. Rev Physiol Biochem Pharmacol 2003;146:55–94.
   PubMed Web of Science ®Google Scholar
• Halic M, Gartmann M, Schlenker O, et al. Signal recognition particle receptor exposes the ribosomal translocon binding site. Science 2006;312:745–747.
   PubMed Web of Science ®Google Scholar
• Halic M, Blau M, Becker T, et al. Following the signal sequence from ribosomal tunnel exit to signal recognition particle. Nature 2006;444:507–511.
   PubMed Web of Science ®Google Scholar
• Siegel V, Walter P. Removal of the Alu structural domain from signal recognition particle leaves its protein translocation activity intact. Nature. 1986;320:81–84.
   PubMedGoogle Scholar
• Liu Y, Zhu X, Zhu J, et al. Identification of differential expression of genes in hepatocellular carcinoma by suppression subtractive hybridization combined cDNA microarray. Oncol Rep 2007;18:943–951.
   PubMed Web of Science ®Google Scholar
• Rho JH, Qin S, Wang JY, Roehrl MH. Proteomic expression analysis of surgical human colorectal cancer tissues: up-regulation of PSB7, PRDX1, and SRP9 and hypoxic adaptation in cancer. J Proteome Res 2008;7:2959–2972.
   PubMed Web of Science ®Google Scholar